FDA approves earlier use of Carvykti CAR-T for multiple myeloma
The FDA has approved ciltacabtagene autoleucel for earlier use in certain adults with relapsed or refractory multiple myeloma. Ciltacabtagene autoleucel (Carvykti; Janssen, Legend Biotech), also known as cilta-cel, is a B-cell maturation antigen (BCMA)-directed CAR T cell therapy previously approved for use in adults with relapsed or refractory multiple myeloma after four lines of treatment. […]